

HR 3002

PATIENTS Act of 2009

Congress: 111 (2009–2011, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 23, 2009

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jun 24, 2009)

Official Text: <https://www.congress.gov/bill/111th-congress/house-bill/3002>

Sponsor

Name: Rep. Boehner, John A. [R-OH-8]

Party: Republican • State: OH • Chamber: House

Cosponsors (4 total)

| Cosponsor | Party / State | Role | Date Joined |
|---------------------------------|---------------|------|--------------|
| Rep. Cantor, Eric [R-VA-7] | R · VA | | Jun 23, 2009 |
| Rep. Blunt, Roy [R-MO-7] | R · MO | | Oct 1, 2009 |
| Rep. Goodlatte, Bob [R-VA-6] | R · VA | | Nov 5, 2009 |
| Rep. Pitts, Joseph R. [R-PA-16] | R · PA | | Nov 5, 2009 |

Committee Activity

| Committee | Chamber | Activity | Date |
|-------------------------------|---------|-------------|--------------|
| Energy and Commerce Committee | House | Referred to | Jun 24, 2009 |
| Ways and Means Committee | House | Referred To | Jun 23, 2009 |

Subjects & Policy Tags

Policy Area:

Health

Related Bills

| Bill | Relationship | Last Action |
|------------|----------------|--|
| 111 S 1259 | Identical bill | Jun 15, 2009: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S6585) |

Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2009 or the PATIENTS Act of 2009 - Prohibits the Secretary of Health and Human Services (HHS) from using data obtained from the conduct of comparative effectiveness research, including such research that is conducted or supported using funds appropriated under the American Recovery and Reinvestment Act of 2009, to deny coverage of an item or service under a federal health care program. Requires the Secretary to ensure that comparative effectiveness research conducted or supported by the federal government accounts for factors contributing to differences in the treatment response and preferences of patients, including patient-reported outcomes, genomics and personalized medicine, the unique needs of health disparity populations, and indirect patient benefits.

Actions Timeline

- **Jun 24, 2009:** Referred to the Subcommittee on Health.
- **Jun 23, 2009:** Introduced in House
- **Jun 23, 2009:** Referred to House Energy and Commerce
- **Jun 23, 2009:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Jun 23, 2009:** Referred to House Ways and Means